Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC2993 (Exenatide) and Daclizumab in Type 1 Diabetes
NCT00064714Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2003
- Primary completion
- Mar 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exenatide in type 1 diabetes mellitus (T1D) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in basal C-peptide level at 6 months. Started Jul 2003; status: completed.
02
Drugs
exenatide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00064714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064714.